ArticleEuropean journal of cancer (Oxford, England : 1990)2022

De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer.

Alex K Bryant et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.